Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Impact of methylphenidate formulation on treatment patterns and hospitalizations: a retrospective analysis"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Impact of methylphenidate formulation on treatment patterns and hospitalizations: a retrospective analysis. | BioMed Central Annals of General Psychiatry Primary research Open Access Impact of methylphenidate formulation on treatment patterns and hospitalizations a retrospective analysis Jason E Kemner1 and Maureen J Lage 2 Address Associate Director Outcomes Research McNeil Consumer and Specialty Pharmaceuticals Fort Washington PA 19034 USA and 2Managing Member HealthMetrics Outcomes Research Groton CT USA Email Jason E Kemner - jkemner@ethus.jnj.com Maureen J Lage - lagemj@hlthmetrics.com Corresponding author Published 10 April 2006 Received 06 May 2005 Annals of General Psychiatry2006 5 5 doi 10.1186 1744-859X-5-5 Accepted I0 April 2006 This article is available from http www.annals-general-psychiatry.cOm content 5 1 5 2006Kemner and Lage licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background While stimulant therapy has been shown to be effective in the treatment of attention-deficit hyperactivity disorder ADHD there is less information concerning differences between alternative stimulant medications. The purpose of this study is to examine how different formulations of methylphenidate MPH affect treatment patterns and hospitalizations. Methods From a large claims database we retrospectively identified individuals age 6 or older who were diagnosed with ADHD and who received either once daily extended-release oral system methylphenidate OROS MPH e.g. Concerta or three-times daily immediate-release generic methylphenidate TID MPH . There were 5 939 individuals included in the analysis - 4 785 who initiated therapy with OROS MPH and 1 154 who initiated therapy with TID MPH. We used Analyses of Covariance ANCOVAs to examine differences in treatment patterns between individuals who initiated therapy on OROS MPH and those